Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis
Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis
复制标题
DOI：
10.1016/j.jhep.2012.10.013
复制
发表时间：
2013-02-01
影响因子：
25.7
通讯作者：
Chapman, Roger W.
中科院分区：
文献类型：
--
作者：
Al Mamari, Said;Djordjevic, Jelena;Chapman, Roger W.
目的：最近发现血清碱性磷酸酶（SAP）正常化与原发性硬化性胆管炎（PSC）预后较好相关。我们的目的是评估SAP改善到低于1.5正常上限（ULN）对这胆汁淤积性肝病预后的影响。方法：牛津PSC数据库筛选1980年至2004年诊断的病例。对符合入选标准的病例进行回顾性检查，以确定临床参数、实验室检查值和临床终点（肝功能失代偿、肝移植和肝脏相关死亡，包括胆管癌）。随访至2010年12月31日。结果：共纳入139例患者，男性87例。55例（40%）患者在中位时间2年内实现SAP改善至1.5 ULN以下，而84例（60%）患者未实现。3/55例（6%）SAP改善患者达到终点，相比之下，32/84例（38%）SAP无改善患者达到终点（p
Background 82 Aims: Normalization of serum alkaline phosphatase (SAP) was recently shown to correlate with better prognosis in Primary Sclerosing Cholangitis (PSC). We aimed at evaluating the impact of SAP improvement to below 1.5 the upper limit of normal (ULN) on the prognosis of this cholestatic liver disease.Methods: Oxford PSC database was screened for cases diagnosed between 1980 and 2004. Cases which met the inclusion criteria were retrospectively examined for clinical parameters, laboratory values, and clinical end points (liver decompensation, liver transplantation, and liver-related deaths including cholangiocarcinoma). Cases were followed-up to 31/12/2010.Results: 139 patients were included, (87 males). Improvement of SAP to below 1.5 ULN was achieved by 55 (40%) patients in a median time of 2 years, compared to 84 (60%) who did not. 3/55 (6%) patients with SAP improvement reached an end point compared to 32/84 (38%) patients with no SAP improvement (p